If you suffer from irritable bowel syndrome, the IBS-C type, and you have not tried Amitzia…you could really be missing out on an effective treatment.
Many people who suffer from IBS-C notice that over time, laxatives that once worked begin to lose their steam.
They ultimately become ineffective and the patient is back to square one with their constipation.
Amitzia (generic name lubiprostone) has been FDA approved for treating chronic constipation of unknown origin.
Effectiveness of Amitzia for IBS-C
This medication hardly ever causes any serious side effects, and occasionally may cause nausea.
Studies have shown the effectiveness of Amitzia for treating the constipation of irritable bowel syndrome.
A study in Gastroenterology (June 2007, Drossman et al) concluded that Amitzia generated relief of IBS after two, 12 week trials.
A paper in Alimentary Pharmacology and Therapeutics (Jan. 2008, Johanson et al) states, “Lubiprostone significantly improved gastrointestinal symptoms of irritable bowel syndrome with constipation at all doses.”
However, points out this report, higher doses (especially 48 μg/day) “were associated with more gastrointestinal adverse events.
The study showed that the optimal combination of efficacy and safety was a 16 μg/day dose.
A later study (Alimentary Pharmacology and Therapeutics, Jan. 2012, Chey et al) found that 8 mcg twice daily of Amitzia was “safe and well tolerated over 9-13 months of treatment.”